{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:24:57Z","timestamp":1775661897438,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006380","name":"Rehabilitation Research and Development Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006380","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jneuroim.2022.577928","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T02:27:09Z","timestamp":1657765629000},"page":"577928","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic"],"prefix":"10.1016","volume":"370","author":[{"given":"Hannah","family":"Kelly","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Collin","family":"Jakubecz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hesham","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2022.577928_bb0005","article-title":"Residual symptoms and long-term outcomes after all-cause autoimmune encephalitis in adults","volume":"434","author":"Abboud","year":"2021","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions: a systematic review","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1474-4422(06)70552-X","article-title":"Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study","volume":"5","author":"Barcellos","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0025","first-page":"1","article-title":"Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder","volume":"0","author":"Butler","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0030","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11060-015-1727-z","article-title":"Myelopathy following intrathecal chemotherapy in adults: a single institution experience","volume":"122","author":"Cachia","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0035","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/annrheumdis-2015-208490","article-title":"Risk of multiple sclerosis during tumour necrosis factor inhibitor treatment for arthritis: a population-based study from DANBIO and the Danish Multiple Sclerosis Registry","volume":"75","author":"Dreyer","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0040","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008157","article-title":"Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis","volume":"93","author":"Farez","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0045","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000213","article-title":"Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer","volume":"2","author":"Granier","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0055","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0060","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/135245859600100619","article-title":"Inhibitors of tumor necrosis factor-\u03b1: promising agents for the treatment of multiple sclerosis?","volume":"1","author":"Hohlfeld","year":"1996","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577259","article-title":"Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab","volume":"344","author":"Kapadia","year":"2020","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0075","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11910-017-0742-1","article-title":"CNS demyelination with TNF-\u03b1 blockers","volume":"17","author":"Kemanetzoglou","year":"2017","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0080","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/1352458519828601","article-title":"Iatrogenic CNS demyelination in the era of modern biologics","volume":"25","author":"Kumar","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0085","doi-asserted-by":"crossref","first-page":"85","DOI":"10.7224\/1537-2073.2018-104","article-title":"Case report: postvaccination anti\u2013myelin oligodendrocyte glycoprotein neuromyelitis optica spectrum disorder","volume":"22","author":"Kumar","year":"2020","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0090","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jamaneurol.2020.1162","article-title":"Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events","volume":"77","author":"Kunchok","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.msard.2018.08.029","article-title":"NMOSD with anti-MOG antibodies following anti-TNF\u03b1 therapy: a case report","volume":"26","author":"Lommers","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0100","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/WCO.0b013e3283398c96","article-title":"Demyelination as a complication of new immunomodulatory treatments","volume":"23","author":"Lysandropoulos","year":"2010","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","article-title":"Neurologic adverse events of immune checkpoint inhibitors: a systematic review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00415-020-10341-4","article-title":"NMDAR antibody encephalitis overlapping with CLIPPERS syndrome in a psoriasis patient on adalimumab","volume":"268","author":"Martin","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0115","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.msard.2018.05.003","article-title":"Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder","volume":"23","author":"Mealy","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102451","article-title":"Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events","volume":"46","author":"Nasralla","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0135","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/ard.2006.066787","article-title":"Optic neuritis occurring with anti-tumour necrosis factor \u03b1 therapy","volume":"66","author":"Simsek","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12887-021-02698-w","article-title":"Assessing causality by means of the Naranjo scale in a paediatric patient with life threatening respiratory failure after alemtuzumab administration: a case report","volume":"21","author":"Smeets","year":"2021","journal-title":"BMC Pediatr."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0145","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1352458511412996","article-title":"Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors","volume":"17","author":"Solomon","year":"2011","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0150","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.4103\/0976-500X.120951","article-title":"Annual report on adverse events related with vaccines use in Calabria (Italy): 2012","volume":"4","author":"Staltari","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0155","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/art.40043","article-title":"Review: immune-related adverse events with use of checkpoint inhibitors for immunotherapy of Cancer","volume":"69","author":"Suarez-Almazor","year":"2017","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0160","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1177\/1352458508096868","article-title":"CNS demyelination and quadrivalent HPV vaccination","volume":"15","author":"Sutton","year":"2009","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0165","first-page":"457","article-title":"The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS\/MRI Analysis Group","volume":"53","author":"TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2022.577928_bb0170","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: a systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0175","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.25764","article-title":"Value of onconeural antibodies in checkpoint inhibitor-related toxicities","volume":"88","author":"Vogrig","year":"2020","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0180","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2022.577928_bb0185","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2012.06.023","article-title":"Initiation of anti-TNF therapy and the risk of optic neuritis; from the safety assessment of biologic ThERapy (SABER) study","volume":"155","author":"Winthrop","year":"2013","journal-title":"Am J. Ophthalmol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822001230?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572822001230?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:41:26Z","timestamp":1759048886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572822001230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":37,"alternative-id":["S0165572822001230"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577928","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of iatrogenic CNS inflammation at a tertiary neuroimmunology clinic","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2022.577928","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577928"}}